Marathon effort to support cancer care

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 12
Volume 17
Issue 12

Oncologist Howard Hochster, MD, professor of medicine at New York University Cancer Institute, ran the 2008 New York City Marathon to benefit Team Continuum which provides immediate nonmedical support and assistance to cancer patients and their families.

Oncologist Howard Hochster, MD, professor of medicine at New York University Cancer Institute, ran the 2008 New York City Marathon to benefit Team Continuum which provides immediate nonmedical support and assistance to cancer patients and their families. Dr. Hochster (right) is pictured with fellow runner Geraldo Rivera (not the TV personality). Mr. Rivera’s 11-year-old daughter is a brain cancer patient and a Team Continuum grant recipient. Dr. Hochster and Mr. Rivera were among 400 runners supporting Team Continuum. The non-profit organization raised more than $5.5 million last year to fund their cancer care and support efforts.

The organization is currently enrolling runners for the April 20, 2009, Boston marathon. For more information, go to www.teamcontinuum.net.

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content